Chemical inhibitors of PSG5 include a variety of compounds that target different signaling pathways involved in the function of this protein. Maraviroc, a CCR5 antagonist, inhibits PSG5 by blocking the CCR5 receptor, which is crucial for PSG5-mediated cell signaling. By obstructing this receptor, Maraviroc prevents PSG5 from engaging in its normal cellular roles. Similarly, GW9662, a PPARγ antagonist, inhibits PSG5 by impeding PPARγ-dependent pathways, which could be integral to the processes mediated by PSG5 within the cell. Another inhibitor, PD173074, which targets FGFR1 kinase, can inhibit PSG5 by disrupting the downstream signaling that is required for PSG5's function. FGFR1 may play a role in pathways that PSG5 uses to facilitate various cellular processes, and inhibition of this receptor can therefore inhibit PSG5 activity.
Other inhibitors operate within the kinase signaling cascades that are likely to be involved in PSG5's cellular functions. LY294002 and Wortmannin are PI3K inhibitors that inhibit PSG5 by blocking the PI3K/Akt signaling pathway, a critical pathway for many cellular functions that PSG5 may influence. The JNK inhibitor SP600125 can inhibit PSG5 by preventing the JNK-mediated signaling required for PSG5's cellular role. SB203580 and PP242, which inhibit p38 MAP kinase and mTOR respectively, can also inhibit PSG5 by interfering with their respective signaling pathways which are potentially implicated in PSG5's cellular activities. Similarly, Rapamycin inhibits PSG5 by disrupting mTOR signaling pathways that PSG5 might utilize. Dasatinib, an Src family kinase inhibitor, inhibits PSG5 by blocking Src kinase activity, a kinase potentially involved in PSG5's signaling pathways. U0126 inhibits PSG5 by preventing the activation of ERK1/2, a kinase that may play a role in PSG5's cellular signaling pathways. Lastly, Axitinib, a VEGFR-specific tyrosine kinase inhibitor, inhibits PSG5 by disrupting VEGF signaling, which is essential for the signaling processes PSG5 is involved in within the cellular environment.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GW 9662 | 22978-25-2 | sc-202641 | 5 mg | $68.00 | 30 | |
GW9662 is a PPARγ antagonist that can inhibit PSG5 by blocking PPARγ-dependent pathways, which could be involved in PSG5-mediated processes in cells. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $46.00 $140.00 $680.00 | 16 | |
PD173074 is an FGFR1 kinase inhibitor, and by inhibiting FGFR1, it could disrupt downstream signaling required for PSG5 function, as FGFR1 may be involved in pathways that are necessary for PSG5's role in cell processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that can inhibit PSG5 by inhibiting PI3K/Akt signaling, which may be implicated in the pathways that regulate PSG5 function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that can inhibit PSG5 by preventing JNK-mediated signaling, which may be necessary for PSG5's role in cellular functions. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor, which can inhibit PSG5 by disrupting p38 MAPK signaling pathways that could be implicated in the cellular functions of PSG5. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which can lead to the inhibition of PSG5 by interfering with mTOR signaling pathways that PSG5 may utilize in its cellular role. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $56.00 $169.00 | 8 | |
PP242 is a selective mTOR inhibitor that can inhibit PSG5 by targeting mTOR signaling, which might be involved in the regulation of PSG5 activity in cells. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a PI3K inhibitor that can inhibit PSG5 by blocking PI3K-dependent signaling pathways, potentially involved in PSG5 function. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is an Src family kinase inhibitor that can inhibit PSG5 by blocking Src kinase activity, which may be involved in signaling pathways important for PSG5's cellular functions. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an MEK inhibitor that can inhibit PSG5 by preventing the activation of ERK1/2, which might be involved in the signaling pathways that PSG5 uses in its cellular role. | ||||||